Pharma Marketing News
News & Views for
Responsible Marketers

Messages from Our Sponsors

Pharma Glossary

Pharmaguy's Picks

Pharma Marketing Network Curated Content Forums
The Leading Online Source of Curated Content for Pharmaceutical Marketing Experts
Newsletter | Conferences | Podcasts | Glossary | Surveys | Blog | Advertising Information | Contact Us

"Must Read Blog for Insiders." -- Wall Street Journal
Pharma Marketing News
Current Issue of Pharma Marketing News Available!

Search the Entire Pharma Marketing Forums Site

Go Back   Pharma Marketing Network Curated Content > News & Views > Pharmaguy's News & Views Picks

Pharmaguy's News & Views Picks A collection of abstracts and links to pharmaceutical industry news and opinions curated by Pharmaguy™, a highly regarded industry pundit.

Thread Tools Rate Thread Display Modes
Old 19th January 2013, 09:52 AM
pharmaguy's Avatar
pharmaguy pharmaguy is offline
Platinum Member
Join Date: Dec 2009
Location: USA
Posts: 400
Default How to Fix Pharma's Rep

January 19, 2013

(Also see the Pharmaguy SM Pioneer Daily:

[Contents: How to Fix Pharma Rep]

Pharma's Reputation Continues to Suffer -- What Can Be Done To Fix It
John LaMattina - Forbes

You don’t have too look far to find unflattering articles about the pharmaceutical industry. What was previously the domain of industry critics like Marcia Angell, Ray Moynihan and the newest entrant to the field, Ben Goldacre, has now grown to include popular television programs such as The Dr. Oz Show. When Dr. Oz, who has over 4 million daily viewers, devotes the bulk of a show to “Four Secrets Drug Companies Don’t Want You To Know”, the industry has got a problem.

In fairness to pharma, it has been trying to improve in these areas. But it is time for the industry to redouble its efforts. As I have outlined in Devalued & Distrusted – Can the pharma industry restore its broken image?, here are some thoughts.

Learn LaMatinna’s suggested “fixes” here...

Read these related articles:

A Voluntary Industry Code For Releasing Trial Data?

n the latest move to pressure the pharmaceutical industry to release clinical trial data, the Health Committee at the UK’s National Institute for Health and Clinical Excellence has issued a report calling for drugmakers to place all information in “the public domain” and create a voluntary code for publicly releasing trial data for drugs once they have been reviewed and made available for clinical use.

“The committee believes there should be both a professional and legal obligation to ensure that all regulators, including NICE, have access to all the available research data about the efficacy and safety of pharmaceutical products,” the January 8 report states. “All information arising from drug trials should be in the public domain in an accessible and properly anonymised form, including any negative information.”

“The committee does not believe it should be either legal or considered ethical to withhold research data about pharmaceutical products. It is, therefore, concerned that this simple principle is not universally applied in practice, and also concerned by the implication of Sir Andrew Dillon’s evidence that NICE are making appraisals of drugs without having access to all relevant data,” the committee concludes. Dillon is the NICE ceo.

Read the full story here...

Read this related article:

(Also see the Pharmaguy SM Pioneer Daily:
Pharmaguy(tm) is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News

Follow me on TWITTER:

On the web:
Reply With Quote

Thread Tools
Display Modes Rate This Thread
Rate This Thread:

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is On
Forum Jump

All times are GMT -5. The time now is 01:23 PM.

Powered by vBulletin® Version 3.6.4
Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.
(c) 2014, Pharma Marketing Network. All rights reserved.